Stewart D J, Dahrouge S
Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Canada.
J Neurooncol. 1995;24(3):299-301. doi: 10.1007/BF01052847.
A 56 year old women was treated with megestrol acetate (Megace) 40 mg p.o. q.i.d. for her cerebellar metastasis of primary adenocarcinoma of the breast. She had previously undergone two surgical resections of her brain metastasis, and a course of radiotherapy. After failing to tolerate tamoxifen therapy, she received Megace, with marked improvement in her cerebellar tumor on CT scans. Despite good control of her brain tumor with Megace, she developed progressive neurological symptoms thought to be due to meningeal carcinomatosis, and died two years after initiating Megace therapy. We conclude that Megace could potentially be beneficial in some patients with brain metastases from adenocarcinoma of the breast.
一名56岁女性因乳腺原发性腺癌小脑转移,接受口服醋酸甲地孕酮(Megace)40毫克,每日4次治疗。她之前曾对脑转移瘤进行过两次手术切除,并接受过一个疗程的放疗。在无法耐受他莫昔芬治疗后,她接受了Megace治疗,CT扫描显示其小脑肿瘤有明显改善。尽管Megace对她的脑肿瘤控制良好,但她出现了进行性神经症状,被认为是由于脑膜癌转移所致,在开始Megace治疗两年后死亡。我们得出结论,Megace可能对某些乳腺腺癌脑转移患者有益。